SCHEMBL5736034

SCHEMBL5736034

O=C1NN(c2ccc(I)cc2)C(=O)C1=CC=Cc1ccco1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 16/20 0.79
KMT2A Q03164 16/20 0.79
MAPT P10636 15/20 0.79
POLB P06746 11/20 0.79
ALDH1A1 P00352 8/20 0.79
L3MBTL1 Q9Y468 7/20 0.79
KDM4E B2RXH2 3/20 0.79
RECQL P46063 14/20 0.74
NPSR1 Q6W5P4 10/20 0.55
MAPK1 P28482 9/20 0.55
MITF O75030 8/20 0.55
PKM P14618 5/20 0.55
GFER P55789 3/20 0.55
HTT P42858 5/20 0.55
HPGD P15428 4/20 0.55
LMNA P02545 4/20 0.55
XBP1 P17861 2/20 0.55
GAA P10253 1/20 0.55
SMN1; SMN2 Q16637 2/20 0.54
ABL1 P00519 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5736031 1.00 MEN1 (0.79) MEN1KMT2AMAPTPOLBALDH1A1
SCHEMBL5734258 0.85 ABL1 (0.64) MEN1KMT2AMAPTPOLBALDH1A1
SCHEMBL5734261 0.85 ABL1 (0.64) MEN1KMT2AMAPTPOLBALDH1A1
SCHEMBL3755954 0.73 ITGA4 (0.65) MEN1KMT2AMAPTPOLBALDH1A1
SCHEMBL3755958 0.73 ITGA4 (0.65) MEN1KMT2AMAPTPOLBALDH1A1
SCHEMBL3757779 0.73 NR4A1 (0.64) MEN1KMT2AMAPTPOLBALDH1A1
SCHEMBL3757780 0.73 NR4A1 (0.64) MEN1KMT2AMAPTPOLBALDH1A1
SCHEMBL5735689 0.72 NR4A1 (0.63) MEN1KMT2AMAPTPOLBALDH1A1
SCHEMBL5735693 0.72 NR4A1 (0.63) MEN1KMT2AMAPTPOLBALDH1A1
SCHEMBL5737024 0.69 ABL1 (1.00) MEN1KMT2APOLBGAAABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1399156-B1 ALKYLIDENE PIRAZOLIDINEDIONE DERIVATIVES AND THEIR USE FOR TREATING DIABETES AND OBESITY APPLIED RESEARCH SYSTEMS (AN) 2006-11-22 EP claimed
US-20040220188-A1 Alkylidene pyrazolidinedione derivatives LABORATOIRES SERONO SA (CH) 2004-11-04 US claimed
EP-1399156-B1 ALKYLIDENE PIRAZOLIDINEDIONE DERIVATIVES AND THEIR USE FOR TREATING DIABETES AND OBESITY APPLIED RESEARCH SYSTEMS (AN) 2006-11-22 EP disclosed
US-20040220188-A1 Alkylidene pyrazolidinedione derivatives LABORATOIRES SERONO SA (CH) 2004-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220188-A1 Alkylidene pyrazolidinedione derivatives G6PC1, PPM1D, PTPRS MEN1 3799/4885KMT2A 4359/4885MAPT 4820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.